Allergan (AGN) to Present IBS Portfolio Data at ACG Annual Meeting

October 14, 2016 8:01 AM EDT

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Allergan plc (NYSE: AGN) announced that new data from its irritable bowel syndrome portfolio will be featured in two poster presentations at the upcoming American College of Gastroenterology (ACG) Annual Scientific Meeting in Las Vegas, NV, October 14-19, 2016.

The scheduled times (noted in local Pacific Time) of the three VIBERZI® (eluxadoline) presentations in the exhibit hall at The Venetian Hotel are as follows:

  • Efficacy and Safety of Eluxadoline in IBS-D Patients Who Report Prior Inadequate Symptom Control with LoperamideDate and Time: Monday, October 17, 10:30 AM – 4:00 PMPoster Number: P1123Category: Functional Bowel Disease
  • Impact of Baseline Pain Severity on the Efficacy of Eluxadoline in Patients with Irritable Bowel Syndrome with DiarrheaDate and Time: Tuesday, October 18, 10:30 AM – 4:00 PMPoster Number: P1876Category: Functional Bowel Disease

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News

Related Entities

Definitive Agreement

Add Your Comment